 The objective of this pilot project is to investigate the prognostic criteria for sensitivity of Chronic Hepatitis C CHC Genotype 1, patients to IFNa treatment. Signal transduction in peripheral blood mononuclear cell PBMC of control groups will be compared with that of CHC patients. For this study, 20 patients with Hepatitis C virus HCV infection who are to undergo standard antiviral therapy and 10 healthy donors significant others of the HCV subject will be enrolled. Signal transduction will be studied in peripheral blood of CHC subjects before the treatment, after 1 and 3 months of treatment, and 4-6 months following the completion of treatment. 